Vaxcyte, Inc. $PCVX Stake Boosted by Walleye Capital LLC

Walleye Capital LLC boosted its holdings in Vaxcyte, Inc. (NASDAQ:PCVX) by 242.2% in the second quarter, HoldingsChannel.com reports. The firm owned 362,610 shares of the company’s stock after acquiring an additional 256,644 shares during the period. Walleye Capital LLC’s holdings in Vaxcyte were worth $11,788,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently added to or reduced their stakes in the business. AlphaQuest LLC acquired a new stake in shares of Vaxcyte during the first quarter worth $33,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Vaxcyte during the 1st quarter valued at about $35,000. CWM LLC raised its stake in Vaxcyte by 197.3% during the second quarter. CWM LLC now owns 1,680 shares of the company’s stock worth $55,000 after acquiring an additional 1,115 shares during the period. Blue Trust Inc. lifted its holdings in Vaxcyte by 176.7% in the second quarter. Blue Trust Inc. now owns 2,161 shares of the company’s stock worth $70,000 after acquiring an additional 1,380 shares during the last quarter. Finally, Advisors Asset Management Inc. lifted its holdings in Vaxcyte by 81.6% in the first quarter. Advisors Asset Management Inc. now owns 1,929 shares of the company’s stock worth $73,000 after acquiring an additional 867 shares during the last quarter. Institutional investors own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on PCVX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a report on Tuesday, October 14th. Leerink Partners set a $77.00 price objective on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. The Goldman Sachs Group started coverage on Vaxcyte in a research report on Friday, September 12th. They issued a “neutral” rating and a $38.00 target price on the stock. Cowen reissued a “buy” rating on shares of Vaxcyte in a report on Thursday, August 7th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $97.83.

Vaxcyte Price Performance

Shares of PCVX stock opened at $46.07 on Friday. Vaxcyte, Inc. has a 12-month low of $27.66 and a 12-month high of $94.60. The firm has a market capitalization of $6.03 billion, a price-to-earnings ratio of -9.52 and a beta of 1.28. The business has a 50 day simple moving average of $43.94 and a 200 day simple moving average of $36.99.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($1.56) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.27) by ($0.29). During the same period in the prior year, the business posted ($0.83) earnings per share. On average, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.